FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washi

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Ington, D.C. 20549	OMB APPROVAL

- 1										
	OMB Number:	3235-0287								
	Estimated average burden									
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SATO VICKI L						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]										eck all appli Directo Officer	cable) or (give title	g Pers	10% Ov Other (s	vner	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET						3. Date of Earliest Transaction (Month/Day/Year) 12/01/2004										President					
(Street) CAMBRIDGE MA 02139					4. l	f Ame	ndme	nt, Date	e of C	Original	Filed	(Month/Da	Line	5. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(8	State)	(Zip)																		
		Tab	ole I - Noi	n-Deriv	/ativ	e Se	curit	ies A	cqı	uired,	Dis	posed o	f, o	r Ben	eficial	ly Owned	t				
1. Title of Security (Instr. 3)			Date	nsaction h/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		·	Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		(A) or . 3, 4 and	Benefic	es ially Following	Form (D) o	n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) or (D)		Price	Transac (Instr. 3	tion(s)			(11041.4)				
Common Stock			12/0	1/2004					М		7,000	,	A	\$9.5	11:	5,108		D			
Common	Stock			12/0	1/200	4				S ⁽¹⁾		7,000)	D	\$10.6	2 108	8,108	08 D			
Common	Stock															8,	,084 I 401(k			401(k)	
		•	Table II -									osed of, onvertil				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transactior Code (Instr 8)				6. Date Exercisal Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		14)	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactie (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Da: Exc	te ercisabl	e I	Expiration Date	Title		Amount or Number of Shares						
Stock Option	\$9.5	12/01/2004			M			7,000	03/	/14/1996	(2)	12/13/2005		nmon	7,000	\$0	1,062,8	319	D		

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1.
- 2. Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995.

Remarks:

Kenneth S. Boger, Attorney-In-12/02/2004 **Fact**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.